Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
ACADIA Pharmaceuticals Inc is a biotechnology business based in the US. ACADIA Pharmaceuticals shares (ACAD) are listed on the NASDAQ and all prices are listed in US Dollars. ACADIA Pharmaceuticals employs 500 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $15.12 |
|---|---|
| 52-week range | $12.24 - $28.06 |
| 50-day moving average | $17.22 |
| 200-day moving average | $20.74 |
| Wall St. target price | $23.38 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.33 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15.12 from 2022-07-06
| 1 week (2022-06-30) | 7.31% |
|---|---|
| 1 month (2022-06-03) | -15.53% |
| 3 months (2022-04-06) | -44.45% |
| 6 months (2022-01-04) | -35.99% |
| 1 year (2021-07-07) | -36.92% |
|---|---|
| 2 years (2020-07-07) | -73.47% |
| 3 years (2019-07-05) | 27.14 |
| 5 years (2017-07-06) | 28.69 |
| Revenue TTM | $493.1 million |
|---|---|
| Gross profit TTM | $225.6 million |
| Return on assets TTM | -19.64% |
| Return on equity TTM | -41.79% |
| Profit margin | -43.5% |
| Book value | $2.76 |
| Market capitalisation | $2.3 billion |
TTM: trailing 12 months
We're not expecting ACADIA Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, ACADIA Pharmaceuticals's shares have ranged in value from as little as $12.24 up to $28.06. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ACADIA Pharmaceuticals's is 0.6738. This would suggest that ACADIA Pharmaceuticals's shares are less volatile than average (for this exchange).
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.